• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

病例报告:首例因LIPE基因新型复合杂合突变导致的中国家族性部分性脂肪营养不良6型患者。

Case report: First Chinese patient with family partial lipodystrophy type 6 due to novel compound heterozygous mutations in the LIPE gene.

作者信息

Zhou Yimeng, Zhang Lin, Ding Yang, Zhai Yongzhen

机构信息

Department of Infectious Diseases, Shengjing Hospital of China Medical University, Shenyang, China.

出版信息

Front Genet. 2024 Jul 24;15:1417613. doi: 10.3389/fgene.2024.1417613. eCollection 2024.

DOI:10.3389/fgene.2024.1417613
PMID:39113684
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11303181/
Abstract

BACKGROUND

Family partial lipodystrophy (FPLD) is a rare autosomal dominant disease characterized by disorders of variable body fat loss associated with metabolic complications. FPLD6 has only been reported in a limited number of cases. Here, we reported a Chinese FPLD6 patient with compound heterozygous mutations in the lipase E, hormone-sensitive type () gene.

CASE PRESENTATION

A 20-year-old female patient presented with hypertriglyceridemia, diabetes mellitus, hepatomegaly, and hepatic steatosis. Subcutaneous fat was significantly diminished in her face, abdomen, and limbs. The patient was assessed by detailed clinical and biochemical examinations. A liver biopsy showed severe lipodystrophy. In addition, there were retinal changes, peripheral nerve damage, and renal tubular injury. Sequencing was performed on extracted DNA. Genetic analysis revealed that the patient had compound heterozygous mutations in the gene: c.2497_250ldel (p.Glu833LysfsTer22) and c.2705del (p.Ser902ThrfsTer27) heterozygous mutations. Verification revealed that this mutation was inherited from her father and mother, respectively, and that they formed newly discovered compound heterozygous mutations occurring in the gene, causing FPLD6.

CONCLUSION

We reported the first case of FPLD6 in China. Gene analysis demonstrated compound heterozygous mutations in LIPE in this patient. Our case emphasizes the importance of genetic testing in young patients with severe metabolic syndromes.

摘要

背景

家族性部分脂肪营养不良(FPLD)是一种罕见的常染色体显性疾病,其特征为身体脂肪丢失情况各异并伴有代谢并发症。FPLD6仅在少数病例中被报道过。在此,我们报告了一名中国FPLD6患者,其脂肪酶E(激素敏感型)基因存在复合杂合突变。

病例介绍

一名20岁女性患者出现高甘油三酯血症、糖尿病、肝肿大和肝脂肪变性。其面部、腹部和四肢的皮下脂肪明显减少。通过详细的临床和生化检查对该患者进行了评估。肝脏活检显示严重脂肪营养不良。此外,还存在视网膜病变、周围神经损伤和肾小管损伤。对提取的DNA进行了测序。基因分析显示该患者在该基因存在复合杂合突变:c.2497_250ldel(p.Glu833LysfsTer22)和c.2705del(p.Ser902ThrfsTer27)杂合突变。验证表明该突变分别遗传自其父亲和母亲,它们构成了该基因中新发现的复合杂合突变,导致了FPLD6。

结论

我们报告了中国首例FPLD6病例。基因分析表明该患者的LIPE基因存在复合杂合突变。我们的病例强调了对患有严重代谢综合征的年轻患者进行基因检测的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed26/11303181/87467ef4072d/fgene-15-1417613-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed26/11303181/5fac5d7fd816/fgene-15-1417613-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed26/11303181/87467ef4072d/fgene-15-1417613-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed26/11303181/5fac5d7fd816/fgene-15-1417613-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed26/11303181/87467ef4072d/fgene-15-1417613-g002.jpg

相似文献

1
Case report: First Chinese patient with family partial lipodystrophy type 6 due to novel compound heterozygous mutations in the LIPE gene.病例报告:首例因LIPE基因新型复合杂合突变导致的中国家族性部分性脂肪营养不良6型患者。
Front Genet. 2024 Jul 24;15:1417613. doi: 10.3389/fgene.2024.1417613. eCollection 2024.
2
Homozygous LIPE mutation in siblings with multiple symmetric lipomatosis, partial lipodystrophy, and myopathy.患有多发性对称性脂肪瘤病、部分脂肪营养不良和肌病的兄弟姐妹中的纯合子LIPE突变。
Am J Med Genet A. 2017 Jan;173(1):190-194. doi: 10.1002/ajmg.a.37880. Epub 2016 Nov 11.
3
Familial Partial Lipodystrophy-Literature Review and Report of a Novel Variant in Expanding the Spectrum of Disease-Causing Alterations in FPLD3.家族性部分脂肪营养不良——文献综述及一例新变异的报告:扩大FPLD3致病改变的疾病谱
Diagnostics (Basel). 2022 Apr 30;12(5):1122. doi: 10.3390/diagnostics12051122.
4
The renal manifestations of type 4 familial partial lipodystrophy: a case report and review of literature.4 型家族性部分性脂肪营养不良的肾脏表现:病例报告及文献复习。
BMC Nephrol. 2018 May 10;19(1):111. doi: 10.1186/s12882-018-0913-6.
5
Case Report: A New Peroxisome Proliferator-Activated Receptor Gamma Mutation Causes Familial Partial Lipodystrophy Type 3 in a Chinese Patient.病例报告:中国患者的一种新过氧化物酶体增殖物激活受体γ突变导致家族性部分脂肪营养不良 3 型。
Front Endocrinol (Lausanne). 2022 Mar 29;13:830708. doi: 10.3389/fendo.2022.830708. eCollection 2022.
6
LIPE-related lipodystrophic syndrome: clinical features and disease modeling using adipose stem cells.LIPE 相关脂肪营养不良综合征:临床特征及脂肪干细胞疾病建模。
Eur J Endocrinol. 2021 Jan;184(1):155-168. doi: 10.1530/EJE-20-1013.
7
Homozygous and Heterozygous Nuclear Lamin A p.R582C Mutation: Different Lipodystrophic Phenotypes in the Same Kindred.纯合子和杂合子核纤层蛋白A p.R582C突变:同一家族中的不同脂肪营养不良表型。
Front Endocrinol (Lausanne). 2018 Aug 20;9:458. doi: 10.3389/fendo.2018.00458. eCollection 2018.
8
Dunnigan-type familial partial lipodystrophy associated with the heterozygous R482W mutation in LMNA gene - case study of three women from one family.与LMNA基因杂合R482W突变相关的邓尼根型家族性部分脂肪营养不良——来自一个家族的三名女性病例研究
Endokrynol Pol. 2013;64(4):306-11. doi: 10.5603/ep.2013.0010.
9
A study of congenital generalized lipodystrophy (CGL) caused by BSCL2 gene mutation.BSCL2 基因突变致先天性全身性脂肪营养不良症的研究
Yi Chuan. 2022 Oct 20;44(10):926-936. doi: 10.16288/j.yczz.22-222.
10
Atypical generalized lipoatrophy and severe insulin resistance due to a heterozygous LMNA p.T10I mutation.因杂合性LMNA基因p.T10I突变导致的非典型全身性脂肪萎缩和严重胰岛素抵抗。
Arq Bras Endocrinol Metabol. 2008 Nov;52(8):1252-6. doi: 10.1590/s0004-27302008000800008.

引用本文的文献

1
Response to Comment on Foss-Freitas et al. Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy. Diabetes Care 2024;47:653-659.对关于福斯-弗雷塔斯等人的评论的回应。胰高血糖素样肽1激动剂在家族性部分脂肪营养不良患者回顾性研究中的疗效和安全性。《糖尿病护理》2024年;47:653 - 659。
Diabetes Care. 2025 Mar 1;48(3):e32. doi: 10.2337/dci24-0080.

本文引用的文献

1
Patients' perspective on the medical pathway from first symptoms to diagnosis in genetic lipodystrophy.患者对遗传性脂肪萎缩症从首发症状到诊断的医疗路径的看法。
Eur J Endocrinol. 2024 Jan 3;190(1):23-33. doi: 10.1093/ejendo/lvad169.
2
Familial Partial Lipodystrophy: Clinical Features, Genetics and Treatment in a Greek Referral Center.家族性部分性脂肪营养不良:希腊转诊中心的临床特征、遗传学和治疗。
Int J Mol Sci. 2023 Jul 27;24(15):12045. doi: 10.3390/ijms241512045.
3
Forward genetic screening using fundus spot scale identifies an essential role for Lipe in murine retinal homeostasis.
利用眼底斑点尺度进行正向遗传筛选,鉴定出 Lipe 在小鼠视网膜动态平衡中的重要作用。
Commun Biol. 2023 May 17;6(1):533. doi: 10.1038/s42003-023-04870-7.
4
Clinical Spectrum of -Associated Type 2 Familial Partial Lipodystrophy: A Systematic Review.与 2 型家族性部分脂肪营养不良相关的临床谱:系统评价。
Cells. 2023 Feb 24;12(5):725. doi: 10.3390/cells12050725.
5
Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study: Volanesorsen in FPLD; The BROADEN Study.评估volanesorsen治疗家族性部分脂肪营养不良患者代谢并发症的疗效和安全性:BROADEN研究结果:volanesorsen治疗家族性部分脂肪营养不良;BROADEN研究
J Clin Lipidol. 2022 Nov-Dec;16(6):833-849. doi: 10.1016/j.jacl.2022.08.008. Epub 2022 Sep 22.
6
Clinical characteristics and efficacy of pioglitazone in a Japanese patient with familial partial lipodystrophy due to peroxisome proliferator-activated receptor γ gene mutation.吡格列酮对一名因过氧化物酶体增殖物激活受体γ基因突变导致家族性部分脂肪营养不良的日本患者的临床特征及疗效
Endocr J. 2023 Jan 30;70(1):69-76. doi: 10.1507/endocrj.EJ22-0140. Epub 2022 Sep 29.
7
Familial Partial Lipodystrophy-Literature Review and Report of a Novel Variant in Expanding the Spectrum of Disease-Causing Alterations in FPLD3.家族性部分脂肪营养不良——文献综述及一例新变异的报告:扩大FPLD3致病改变的疾病谱
Diagnostics (Basel). 2022 Apr 30;12(5):1122. doi: 10.3390/diagnostics12051122.
8
Case Report: A New Peroxisome Proliferator-Activated Receptor Gamma Mutation Causes Familial Partial Lipodystrophy Type 3 in a Chinese Patient.病例报告:中国患者的一种新过氧化物酶体增殖物激活受体γ突变导致家族性部分脂肪营养不良 3 型。
Front Endocrinol (Lausanne). 2022 Mar 29;13:830708. doi: 10.3389/fendo.2022.830708. eCollection 2022.
9
Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings. metreleptin 治疗非酒精性脂肪性肝炎:两种不同临床环境下的开放标签治疗干预。
Med. 2021 Jul 9;2(7):814-835. doi: 10.1016/j.medj.2021.04.001. Epub 2021 May 12.
10
A missense variant Arg611Cys in LIPE which encodes hormone sensitive lipase decreases lipolysis and increases risk of type 2 diabetes in American Indians.编码激素敏感性脂肪酶的LIPE基因中的一个错义变体Arg611Cys会降低脂肪分解,并增加美洲印第安人患2型糖尿病的风险。
Diabetes Metab Res Rev. 2022 Mar;38(3):e3504. doi: 10.1002/dmrr.3504. Epub 2021 Oct 28.